SouthState Corp’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$77.9K Sell
395
-31,466
-99% -$6.07M ﹤0.01% 408
2025
Q4
$5.86M Buy
31,861
+1,138
+4% +$200K 0.26% 84
2025
Q3
$4.71M Sell
30,723
-952
-3% -$144K 0.22% 95
2025
Q2
$4.43M Buy
31,675
+12
+0% +$1.68K 0.19% 104
2025
Q1
$4.65M Buy
31,663
+283
+0.9% +$40.9K 0.21% 99
2024
Q4
$4.11M Sell
31,380
-994
-3% -$139K 0.27% 86
2024
Q3
$5.04M Buy
32,374
+513
+2% +$82.8K 0.35% 72
2024
Q2
$4.97M Sell
31,861
-134
-0.4% -$20.2K 0.36% 68
2024
Q1
$4.34M Buy
31,995
+854
+3% +$113K 0.34% 77
2023
Q4
$4.19M Sell
31,141
-113
-0.4% -$14.7K 0.36% 71
2023
Q3
$4.23M Sell
31,254
-92
-0.3% -$12.6K 0.4% 63
2023
Q2
$4.49M Sell
31,346
-252
-0.8% -$37.1K 0.4% 62
2023
Q1
$4.39M Sell
31,598
-439
-1% -$59.1K 0.4% 64
2022
Q4
$4.34M Buy
32,037
+262
+0.8% +$32.9K 0.4% 69
2022
Q3
$3.48M Sell
31,775
-1,907
-6% -$242K 0.35% 71
2022
Q2
$4.45M Sell
33,682
-2,029
-6% -$266K 0.42% 62
2022
Q1
$4.74M Buy
35,711
+228
+0.6% +$27.3K 0.38% 68
2021
Q4
$4.13M Sell
35,483
-1,599
-4% -$188K 0.32% 79
2021
Q3
$4.45M Buy
37,082
+192
+0.5% +$22.4K 0.37% 71
2021
Q2
$4.42M Sell
36,890
-784
-2% -$86K 0.38% 69
2021
Q1
$3.75M Sell
37,674
-1,115
-3% -$112K 0.35% 73
2020
Q4
$3.88M Sell
38,789
-2,444
-6% -$259K 0.38% 70
2020
Q3
$4.52M Buy
41,233
+2,510
+6% +$279K 0.47% 59
2020
Q2
$4.1M Buy
38,723
+6,006
+18% +$620K 0.5% 56
2020
Q1
$2.92M Buy
32,717
+5,833
+22% +$549K 0.43% 63
2019
Q4
$2.68M Buy
26,884
+2,052
+8% +$193K 0.31% 84
2019
Q3
$2.21M Sell
24,832
-789
-3% -$68.4K 0.28% 87
2019
Q2
$2.12M Buy
25,621
+144
+0.6% +$11.3K 0.24% 97
2019
Q1
$2.06M Buy
25,477
+1,485
+6% +$117K 0.21% 101
2018
Q4
$1.82M Sell
23,992
-27,539
-53% -$2.15M 0.21% 105
2018
Q3
$4.08M Buy
51,531
+4,334
+9% +$328K 0.42% 81
2018
Q2
$3.31M Buy
47,197
+14,403
+44% +$1.04M 0.37% 86
2018
Q1
$2.29M Buy
+32,794
New +$2.27M 0.26% 100

Other funds holding AZN

SouthState Corp's AZN Position: Q1 2026 in Review

SouthState Corp reduced its AstraZeneca (AZN) stake by 99% in Q1 2026, selling an estimated $6.07M and leaving 395 shares worth $77.9K. The position accounts for ﹤0.01% of the portfolio, ranked #408.

SouthState Corp first reported a position in AZN in Q1 2018 and has held it in 33 quarters since. The position peaked at $5.86M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • SouthState Corp held 395 shares of AstraZeneca worth $77.9K as of Q1 2026.
  • SouthState Corp sold 31,466 AstraZeneca shares in Q1 2026, an estimated $6.07M.
  • AstraZeneca made up ﹤0.01% of SouthState Corp's portfolio in Q1 2026, its #408 holding.
  • SouthState Corp first reported a position in AstraZeneca in Q1 2018 and has held it in 33 quarters since.
  • SouthState Corp's AstraZeneca position peaked at $5.86M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on SouthState Corp's 13F filing for Q1 2026, filed 5 May 2026.